Comparison of Intratympanic, Systemic, and Combined Steroid Therapies for Sudden Sensorineural Hearing Loss in Patients with Diabetes Mellitus

Background: The risk of sudden sensorineural hearing loss associated with metformin use in patients with diabetes mellitus has not been fully examined. Study design: It is a retrospective matched-cohort study. Subjects and methods: We examined the medical records of patients with diabetes mellitus over 18 years old in Taiwan’s National Health Insurance Research Database for the period between 1 January 2000 and 31 December 2013, to establish matched cohorts (14,109 with and 42,327 without metformin use) at a ratio of 1:3 by sex, age and index year. Results: We used a Cox regression hazard model to identify risk factors of sudden sensorineural hearing loss during 14 years of follow-up, and the results indicate that a significantly lower percentage of diabetes mellitus patients with metformin use ( p = 0.033) developed sudden sensorineural hearing loss compared with those without metformin use (0.21%, 29/14,109 vs 0.32%, 136/42,327). After adjustment for age and other variables [adjusted hazard ratio: 0.630 (95% confidence interval: 0.422–0.941, p = 0.024)], this study also demonstrated that metformin use appeared to reduce the risk of developing sudden sensorineural hearing loss. Conclusion: This study demonstrated an association between metformin use and lower incidence of sudden sensorineural hearing loss among patients with diabetes mellitus.

Download Full-text

A Clinical Study of 77 Cases of Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) with Diabetes Mellitus

Practica Oto-Rhino-Laryngologica ◽

10.5631/jibirin.104.11 ◽

2011 ◽

Vol 104 (1) ◽

pp. 11-16 ◽

Cited By ~ 1

Author(s):

Takefumi Kamakura ◽

Naoki Matsushiro ◽

Masashi Furukawa ◽

Takahiro Kitamura ◽

Hiroshi Kajikawa

Keyword(s):

Diabetes Mellitus ◽

Hearing Loss ◽

Clinical Study ◽

Sensorineural Hearing Loss ◽

Sudden Sensorineural Hearing Loss ◽

Sensorineural Hearing

Download Full-text

Increased risk of sudden sensorineural hearing loss in patients with depressive disorders: population-based cohort study

The Journal of Laryngology & Otology ◽

10.1017/s0022215115002960 ◽

2015 ◽

Vol 130 (1) ◽

pp. 42-49 ◽

Cited By ~ 9

Author(s):

C-S Lin ◽

Y-S Lin ◽

C-F Liu ◽

S-F Weng ◽

C Lin ◽

...

Keyword(s):

Diabetes Mellitus ◽

Chronic Kidney Disease ◽

Hearing Loss ◽

Kidney Disease ◽

Sensorineural Hearing Loss ◽

Depressive Disorders ◽

Sudden Sensorineural Hearing Loss ◽

Hazard Ratio ◽

Sensorineural Hearing ◽

Increased Risk

AbstractObjectives:To evaluate the incidence rates and risk of sudden sensorineural hearing loss among patients with depressive disorders.Method:Data for 27 547 patients with newly diagnosed depressive disorders and 27 547 subjects without depressive disorders between 2001 and 2008 were yielded from the Taiwan National Health Insurance Research Database. Sudden sensorineural hearing loss incidence at the end of 2011 was determined. Cumulative incidence and adjusted hazard ratio were computed.Results:Sudden sensorineural hearing loss incidence was 1.45 times higher in the depressive disorders group compared to the non-depressive disorders group (p = 0.0041), with an adjusted hazard ratio of 1.460. A significant increased risk of developing sudden sensorineural hearing loss was noted in patients with diabetes mellitus, chronic kidney disease and hyperlipidaemia (p < 0.05).Conclusion:The results suggest an increased risk of developing sudden sensorineural hearing loss in patients with depressive disorders. Co-morbidities such as diabetes mellitus, chronic kidney disease and hyperlipidaemia significantly aggravated the risk. Depressive disorders might be considered a risk factor for sudden sensorineural hearing loss. It remains to be seen whether control of depressive disorders can decrease the incidence of sudden sensorineural hearing loss in patients with depressive disorders.

Download Full-text

Patterns of Otorhinolaryngological Disorders in Subjects with Diabetes

IIUM Medical Journal Malaysia ◽

10.31436/imjm.v10i2.676 ◽

2020 ◽

Vol 10 (2) ◽

Author(s):

Gazzaz ZJ ◽

Makhdom MN ◽

Dhafar KO ◽

Maimini O ◽

Farooq MU ◽

...

Keyword(s):

Diabetes Mellitus ◽

Hearing Loss ◽

Saudi Arabia ◽

Sensorineural Hearing Loss ◽

Diabetes Mellitus Type 2 ◽

Sensorineural Hearing ◽

Diabetes Mellitus Type ◽

Patients With Diabetes ◽

Hba1c Levels

Objective: To find out the prevalence of otorhinolaryngological disorders in patients with diabetes mellitus who presented to Ear, Nose and Throat (ENT) clinic at Al-Noor specialist hospital, Makkah, Saudi Arabia. Materials & Methods: This observational retrospective study was carried out over a period of one year, from July 15, 2004 to July 20, 2005 by the collaboration of ENT Department and Health Research Center of Al-Noor Specialist Hospital, Makkah, Saudi Arabia. Patients’ information was collected such as the demography, types and durations of diabetes, types of diabetic treatments, and fi nal ENT diagnosis. Subjects’ random blood sugar and hemoglobin A1c (HbA1c) levels were collected on the fi rst visit to the ENT-Outpatient Department. Results: One hundred patients met the inclusion criteria; with mean age of 51.5 years (age range 14-86 years). Thirty-nine percent of the patients were at the age of 45-54 years old. Males (52%) slightly out-numbered the females. Majority had diabetes mellitus type 2 and 78% patients had high HbA1c levels indicating poor glycemic controls. The most common ENT disorder was rhinitis (19%), followed by sensorineural hearing loss (12%) and malignant otitis externa (8%). Conclusion: The most common ENT disorder in patients with diabetes mellitus type 2 was rhinitis, followed by sensorineural hearing loss. Majority of these patients had poor glycemic control, hence can explain the predominance of certain disorders over others.

Download Full-text

Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes

Otolaryngology ◽

10.1016/j.otohns.2009.06.084 ◽

2009 ◽

Vol 141 (5) ◽

pp. 572-578 ◽

Cited By ~ 44

Author(s):

Chi-Sung Han ◽

Jong-Ryul Park ◽

Sung-Hyun Boo ◽

Joon-Man Jo ◽

Kyung-Won Park ◽

...

Keyword(s):

Hearing Loss ◽

Sensorineural Hearing Loss ◽

Initial Treatment ◽

Sudden Sensorineural Hearing Loss ◽

Steroid Treatment ◽

Sensorineural Hearing ◽

Systemic Steroid ◽

Significant Difference ◽

Before And After ◽

Patients With Diabetes

Objective: The purpose of this study is to compare the efficacy of intratympanic steroid injection (ITSI) with that of systemic steroids as an initial treatment of sudden sensorineural hearing loss (SNHL) with diabetes. Study Design: Prospective, nonrandomized multicenter clinical trial. Setting: Multicenter study in Busan and Masan, South Korea. Subjects and Methods: A total of 114 sudden SNHL patients who were diagnosed with diabetes were divided into peroral (PO) group (n = 48), intravenous (IV) group (n = 32), and intratympanic (IT) group (n = 34). In the PO group, prednisolone was used orally for 10 days, per schedule. In the IV group, prednisolone was administered intravenously for seven days, followed by oral administration of tapered doses for another several days. In the IT group, dexamethasone was injected into the tympanic cavity four times within a two-week period. Hearing outcome was assessed before and after the treatment. Results: All groups showed significant improvement with criteria of 15 dB ( P < 0.05). However, there was no significant difference in hearing gain and recovery rate among groups ( P > 0.05). Systemic steroid treatment was stopped for two patients in the IV group and for one in the PO group due to uncontrolled hyperglycemia. However, in the IT group, there were no patients who failed to control their blood sugar level. Conclusion: ITSI is as effective as systemic steroid treatment for sudden SNHL patients with diabetes and it can avoid undesirable side effects. Therefore, we consider ITSI to be a more reasonable alternative as an initial treatment for sudden SNHL patients with diabetes.

Download Full-text

MAGNITUDE OF DIABETES MELLITUS IN PATIENTS OF SUDDEN SENSORINEURAL HEARING LOSS AND ITS EFFECT ON CORTICOSTEROID THERAPY

Pakistan Armed Forces Medical Journal ◽

10.51253/pafmj.v71isuppl-3.7109 ◽

2021 ◽

Vol 71 (Suppl-3) ◽

pp. S626-29

Author(s):

Tahira Sajid ◽

Fatima Sajid ◽

Zara Sajid ◽

Syeda Rifaat Qamar Naqvi ◽

Syed Maisam Ali ◽

...

Keyword(s):

Diabetes Mellitus ◽

Hearing Loss ◽

Sensorineural Hearing Loss ◽

Corticosteroid Therapy ◽

Strong Association ◽

Sudden Sensorineural Hearing Loss ◽

Final Outcome ◽

Sensorineural Hearing ◽

Cross Sectional ◽

Number Of Patients

Objective: To determine the magnitude and effects of diabetes mellitus in patients of sudden sensorineural hearing loss and on the final outcome of therapy. Study Design: Cross sectional study. Place and Duration of Study: ENT unit of Medical Teaching Institution Abbottabad, from Jul 2018 to Jun 2020. Methodology: A total of 84 patients presented who had idiopathic sudden sensorineural hearing loss by using non probability consecutive sampling enrolled in the study. Basic parameters, age, diabetes mellitus and hearing loss were used for data collection. The data was analyzed by using SPSS version 23. Results: Out of total 52 (61.9%) were male and 32 (38.1%) were female, mean age was 45.62 ± 14.12 years from 14-85 years. A large number of patients presented within one week of onset of hearing loss 57 (67.86%). In our patient group 18 patients (21.4%) had diabetes mellitus and 66 patients (78.6%) did not have diabetes mellitus at presentation. Initial Hearing loss at presentation was significantly more in patients who had diabetes mellitus p=0.006 and there was statistically strong association between the final hearing improvement and diabetes mellitus p<0.001. Conclusion: Diabetes mellitus is associated with more severe hearing loss at initial presentation and poorer final outcome in patients with Idiopathic sudden sensorineural hearing loss. As glycemic control does not affect the result so corticosteroid therapy must be given to all patients of sudden sensorineural hearing loss with diabetes mellitus.

Download Full-text